683 Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

683 Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-255,400	Closed	-$3.37M	–	256
2025 Q4	$3.37M	Buy	+255,400	New	+$3.01M	0.15%	97

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

683 Capital Management's MLTX Position: Q2 2022 in Review

683 Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 790,000 shares — an estimated $7.9M sold.

683 Capital Management first reported a position in MLTX in Q4 2020 and held it in 6 quarters. The position peaked at $7.9M in Q1 2022. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

683 Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
683 Capital Management sold 790,000 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $7.9M.
683 Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 6 quarters.
683 Capital Management's MoonLake Immunotherapeutics position peaked at $7.9M in Q1 2022.
23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on 683 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.